vs
Side-by-side financial comparison of CS Disco, Inc. (LAW) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $41.9M, roughly 1.6× CS Disco, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -23.0%, a 62.4% gap on every dollar of revenue.
CS Disco, Inc. is a leading legal technology provider that develops cloud-based software solutions for legal practitioners. Its core offerings include e-discovery, document review, case management, and legal workflow automation tools, serving law firms, corporate legal teams, and government legal departments primarily in North America.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
LAW vs SLNO — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.9M | $66.0M |
| Net Profit | $-9.6M | $26.0M |
| Gross Margin | 74.2% | 98.3% |
| Operating Margin | 1.7% | 33.5% |
| Net Margin | -23.0% | 39.4% |
| Revenue YoY | 14.3% | — |
| Net Profit YoY | 15.6% | 134.0% |
| EPS (diluted) | $-0.15 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $41.9M | — | ||
| Q4 25 | $41.2M | — | ||
| Q3 25 | $40.9M | $66.0M | ||
| Q2 25 | $38.1M | $32.7M | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $36.3M | — | ||
| Q2 24 | $36.0M | — |
| Q1 26 | $-9.6M | — | ||
| Q4 25 | $-8.5M | — | ||
| Q3 25 | $-13.7M | $26.0M | ||
| Q2 25 | $-10.8M | $-4.7M | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | $-25.2M | — | ||
| Q3 24 | $-9.2M | — | ||
| Q2 24 | $-10.8M | — |
| Q1 26 | 74.2% | — | ||
| Q4 25 | 75.1% | — | ||
| Q3 25 | 75.5% | 98.3% | ||
| Q2 25 | 74.6% | 97.9% | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 74.2% | — | ||
| Q3 24 | 73.1% | — | ||
| Q2 24 | 74.2% | — |
| Q1 26 | 1.7% | — | ||
| Q4 25 | -22.4% | — | ||
| Q3 25 | -35.3% | 33.5% | ||
| Q2 25 | -31.0% | -20.0% | ||
| Q1 25 | -34.4% | — | ||
| Q4 24 | -70.6% | — | ||
| Q3 24 | -30.0% | — | ||
| Q2 24 | -34.4% | — |
| Q1 26 | -23.0% | — | ||
| Q4 25 | -20.7% | — | ||
| Q3 25 | -33.4% | 39.4% | ||
| Q2 25 | -28.4% | -14.4% | ||
| Q1 25 | -31.1% | — | ||
| Q4 24 | -68.1% | — | ||
| Q3 24 | -25.3% | — | ||
| Q2 24 | -30.1% | — |
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.22 | $0.47 | ||
| Q2 25 | $-0.18 | $-0.09 | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $-0.43 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.18 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $123.9M | $494.8M |
| Total Assets | $162.4M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $103.0M | — | ||
| Q4 25 | $114.6M | — | ||
| Q3 25 | $113.5M | $498.9M | ||
| Q2 25 | $114.5M | $286.8M | ||
| Q1 25 | $118.8M | — | ||
| Q4 24 | $129.1M | — | ||
| Q3 24 | $126.8M | — | ||
| Q2 24 | $130.0M | — |
| Q1 26 | $123.9M | — | ||
| Q4 25 | $128.1M | — | ||
| Q3 25 | $130.6M | $494.8M | ||
| Q2 25 | $137.9M | $240.1M | ||
| Q1 25 | $142.2M | — | ||
| Q4 24 | $147.5M | — | ||
| Q3 24 | $167.3M | — | ||
| Q2 24 | $170.9M | — |
| Q1 26 | $162.4M | — | ||
| Q4 25 | $173.6M | — | ||
| Q3 25 | $174.8M | $599.9M | ||
| Q2 25 | $164.9M | $332.3M | ||
| Q1 25 | $168.0M | — | ||
| Q4 24 | $180.3M | — | ||
| Q3 24 | $194.4M | — | ||
| Q2 24 | $198.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-11.7M | — | ||
| Q4 25 | $762.0K | — | ||
| Q3 25 | $-979.0K | $43.5M | ||
| Q2 25 | $-4.2M | $-12.6M | ||
| Q1 25 | $-10.5M | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $-2.9M | — | ||
| Q2 24 | $-650.0K | — |
| Q1 26 | — | — | ||
| Q4 25 | $255.0K | — | ||
| Q3 25 | $-2.0M | $43.5M | ||
| Q2 25 | $-5.2M | $-12.6M | ||
| Q1 25 | $-11.0M | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-1.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | -5.0% | 65.8% | ||
| Q2 25 | -13.6% | -38.6% | ||
| Q1 25 | -30.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | -10.3% | — | ||
| Q2 24 | -3.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 2.6% | 0.0% | ||
| Q2 25 | 2.5% | 0.0% | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
